Skip to content

Effect of Pregabalin on Functional Dyspepsia, A Randomized Controlled Study

Effect of Pregabalin on Functional Dyspepsia, A Randomized Controlled Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200404002
Enrollment
82
Registered
2020-04-04
Start date
2020-05-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Dyspepsia Self report of adequate relief Napean dyspepsia Index Functional dyspepsia Pregabalin Self report of adequate relief Napean dyspepsia Index

Interventions

Pregabalin(75) 1 tab once daily for 8 weeks,Placebo 1 tab once daily for 8 weeks
Experimental Drug,Placebo Comparator Drug
Pregabalin,Placebo

Sponsors

Chiang Mai University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diabnosed Funtional dypsepsia according to Rome IV criteria Normal esophagogastroduodenoscopy within 5 years No evidence of Helicobacter pylori infection Partial or non responsder to proton pump inhibitor as standard treatment

Exclusion criteria

Exclusion criteria: History of irritable bowel syndrome Major physical illness e.g. End stage kidney disease Pregnancy and Lactation

Design outcomes

Primary

MeasureTime frame
Self Report of Adequate Relief Week 4, Week 8 Score

Secondary

MeasureTime frame
Short form Napean dyspepsia index Baseline, Week 4, Week 8 Score

Countries

Thailand

Contacts

Public ContactIsariyaphong Kotikula

Chiang Mai University hospital

Exodusisme@gmail.com0810303950

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026